Study yields promising results for skin infection drug

12/21/2012 | Reuters

The antibiotic oritavancin performed comparably with standard-of-care vancomycin in terms of efficacy, according to findings from a late-stage trial. The drug met the primary endpoint of the study, which was to halt the spread of the infection and to eliminate fever. The drug was tested for the treatment of acute bacterial skin and skin structure infections by gram-positive bacteria, including methicillin-resistant Staphylococcus aureus.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL